Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.00%
)
US TECH 100
29,577.20
(
0.15%
)
Dow Jones
51,032.46
(
0.00%
)
Brent Oil
94.75
(
3.71%
)
Bitcoin
71,854.45
(
-2.31%
)
News Focus
News Focus
Post# of 257665
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 169179

Saturday, 11/02/2013 6:53:25 PM

Saturday, November 02, 2013 6:53:25 PM

Post# of 257665

The chances of a patient that has failed both Sprycel and Tasigna responding to Bosulif are negligible in my opinion.

Bosulif gets some use the second-line setting, and such use will presumably increase if your conjecture about changes to the Tasigna label is borne out.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today